Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
12.92
-0.06 (-0.46%)
Official Closing Price
Updated: 7:00 PM EDT, Jun 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
16
17
Next >
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved in Indonesia for Use Regardless of Prior Dengue Exposure
August 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Peering Into Takeda Pharmaceutical's Recent Short Interest
August 08, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has risen 18.18% since its last report. The company recently reported that it has 4.18 million shares sold...
Via
Benzinga
Takeda Delivers Strong First Quarter FY2022 Results; On Track Towards Full-Year Management Guidance
July 28, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder
July 21, 2022
Via
Benzinga
Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22
May 11, 2022
Via
Benzinga
EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets
July 27, 2022
BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome...
Via
Benzinga
Hot Debate Over Myocarditis Risk Shines Spotlight on Heart Disease
July 26, 2022
Palm Beach, FL – July 26, 2022 – FinancialNewsMedia.com News Commentary – As COVID-19 vaccines for kids achieve the Centers for Disease Control and Prevention (CDC) recommendation, concern it could...
Via
FinancialNewsMedia
Exposures
COVID-19
Product Safety
Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents
July 26, 2022
Via
Benzinga
Peering Into Takeda Pharmaceutical's Recent Short Interest
July 21, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 15.38% since its last report. The company recently reported that it has 3.29 million shares sold short, which...
Via
Benzinga
Takeda Announces Positive Topline Results from Pivotal Phase 3 Clinical Trial Evaluating HYQVIA® for Maintenance Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
July 21, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022
July 19, 2022
Upgrades
Via
Benzinga
Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful
July 18, 2022
Via
Benzinga
Takeda Announces the Submission of its Corporate Governance Report to the Tokyo Stock Exchange
July 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Looking Into Takeda Pharmaceutical's Recent Short Interest
July 05, 2022
Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which...
Via
Benzinga
Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years
July 01, 2022
Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.
Via
Benzinga
Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years
June 30, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
June 27, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
June 22, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
As Health Problems Mount Patients Welcome New Treatments
June 14, 2022
Palm Beach, FL – June 14, 2022 – FinancialNewsMedia.com News Commentary – There are several serious health problems facing society today. Some, like heart disease, gastrointestinal diseases, cancer,...
Via
FinancialNewsMedia
Takeda’s Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial
June 09, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Moderna Pops On Updated Booster Data, But Analyst Says It Needs A 'Second Act'
June 08, 2022
Moderna tested a bivalent booster, which targets two Covid strains in one shot.
Via
Investor's Business Daily
Quant Ratings Updated on 66 Stocks
June 06, 2022
Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10.
Via
InvestorPlace
Takeda Presents Latest Research from Oncology Portfolio and Pipeline at ASCO & EHA
May 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
May 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
May 31, 2022
Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance, and commercial activities for SpikevaxTM from August 1,...
From
Moderna, Inc.
Via
AccessWire
Exposures
COVID-19
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
May 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Current Report: Takeda Pharmaceutical
May 18, 2022
Takeda’s price per share was $14.31 as of yesterday's market close. One year ago its price was $17.20.
Via
Talk Markets
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
May 11, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
April 26, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients
April 22, 2022
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.